1.Mechanism and clinical significance of HBV reactivation after anti-HCV therapy.
Wan Jia ZENG ; Lin GAO ; Yi Wei XU ; Xiang Mei CHEN ; Fu Sheng WANG ; Feng Min LU
Chinese Journal of Hepatology 2022;30(9):997-1001
Direct-acting antivirals (DAAs) can strongly inhibit the replication of hepatitis C virus (HCV) and effectively clear the infection, but it may cause hepatitis B virus (HBV) reactivation, leading to severe liver damage and fulminate hepatitis in patients with HCV/HBV coinfection. In this review, we summarized the different replication process of HCV and HBV in infected hepatocytes and consequent innate immune response, and then discussed the molecular mechanism and clinical significance of HBV reactivation, and put forward the clinical precaution.
Humans
;
Hepatitis B virus
;
Hepacivirus
;
Antiviral Agents/pharmacology*
;
Hepatitis C, Chronic/drug therapy*
;
Virus Activation
;
Hepatitis C/drug therapy*
;
Coinfection/drug therapy*
;
Hepatitis B/drug therapy*
5.Advances in new antivirals for chronic hepatitis B.
Yanhua TANG ; Hongyan LIANG ; Ge ZENG ; Sheng SHEN ; Jian SUN
Chinese Medical Journal 2022;135(5):571-583
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.
Antiviral Agents/therapeutic use*
;
Hepatitis B/drug therapy*
;
Hepatitis B Surface Antigens
;
Hepatitis B virus
;
Hepatitis B, Chronic/drug therapy*
;
Hepatitis C, Chronic/drug therapy*
;
Humans
6.Antiviral therapy for hepatitis C.
Chinese Journal of Hepatology 2004;12(2):105-105
8.Clinical Implications of Chemokines in Acute and Chronic Hepatitis C Virus Infection.
Yonsei Medical Journal 2011;52(6):871-878
Hepatitis C virus (HCV), a non-cytopathic positive-stranded RNA virus, is one of the most common causes of chronic liver diseases such as chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Upon HCV infection, the majority of patients fail to clear the virus and progress to chronic hepatitis C. Chemokines are small chemotactic cytokines that direct the recruitment of immune cells and coordinate immune responses upon viral infection. Chemokine production during acute HCV infection contributes to the recruitment of immune cells with antiviral effector functions and subsequent viral clearance. In chronic HCV infection, however, continuous production of chemokines due to persistent viral replication might result in incessant recruitment of inflammatory cells to the liver, giving rise to persistence of chronic inflammation and liver injury. In this review, we will summarize the roles of chemokines in acute and chronic settings of HCV infection and the clinical relevance of chemokines in the treatment of hepatitis C.
Antiviral Agents/therapeutic use
;
Chemokines/*metabolism
;
Hepatitis C/drug therapy/*immunology/*metabolism
;
Hepatitis C, Chronic/drug therapy/*immunology/*metabolism
;
Humans
10.Monitoring antibody titers to recombinant Core-NS3 fusion polypeptide is useful for evaluating hepatitis C virus infection and responses to interferon-alpha therapy.
Young Min PARK ; Byung Hun BYUN ; Jong Young CHOI ; Si Hyun BAE ; Boo Sung KIM ; Hong Soeb SO ; Wang Shick RYU
Journal of Korean Medical Science 1999;14(2):165-170
To evaluate the clinical feasibility of the antibody titer against a chimeric polypeptide (named Core 518), in which a domain of Core and NS3 of hepatitis C virus (HCV) was fused, ELISA was performed in a total of 76 serum samples. Each serum was serially diluted using two-fold dilution method with distilled water into 10 concentrations. They were all positive for second generation anti-HCV assay (HCV EIA II; Abbott Laboratories). Genotyping RT-PCR, quantitative competitive RT-PCR, and RIBA (Lucky Confirm; LG Biotech) were also assayed. Anti-Core 518 antibody was detected in x 12800 or higher dilutions of sera from 35 of 43 chronic hepatitis C (81.4%) and nine of 16 hepatocellular carcinoma sera (56.3%), one of four cirrhosis (25%), 0 of four acute hepatitis C, and one of nine healthy isolated anti-HCV-positive subjects (p=0.0000). The anti-Core 518 antibody titers were well correlated with the presence of HCV RNA in serum (p=0.002). The anti-Core 518 antibody titers decreased significantly in nine of ten responders to IFN-alpha treatment. Monitoring anti-Core 518 titers may be helpful not only for differentiating the status of HCV infection among patients with various type C viral liver diseases, but also for predicting responses to IFN-alpha treatment.
Adult
;
Aged
;
Female
;
Genotype
;
Hepatitis C/immunology*
;
Hepatitis C/drug therapy*
;
Hepatitis C/diagnosis
;
Hepatitis C/blood
;
Hepatitis C Antibodies/immunology*
;
Hepatitis C Antibodies/blood
;
Hepatitis C Antigens/immunology*
;
Hepatitis C-Like Viruses/immunology*
;
Hepatitis C-Like Viruses/genetics
;
Human
;
Immunoblotting
;
Interferon Alfa-2a/therapeutic use*
;
Male
;
Middle Age
;
RNA, Viral/blood
;
Recombinant Fusion Proteins/immunology
;
Viral Core Proteins/immunology*
;
Viral Nonstructural Proteins/immunology*